May 3rd 2024
Findings from a real-world study identified that venetoclax was a safe treatment option and did not lead to higher rates of death for patients with chronic lymphocytic leukemia who were diagnosed with COVID-19.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Prognostic Information in AML Gleaned From Timing of Genetic Mutations
September 2nd 2015A new study suggests that the presence of persistent genetic mutations, 30 days after induction chemotherapy, predicted relapse and survival in patients with acute myeloid leukemia (AML), as well as intermediate-risk patients.
Read More
Venetoclax FDA Submission Imminent Following Phase II CLL Success
August 13th 2015Venetoclax (ABT-199) monotherapy showed promising phase II results, which will be submitted to regulatory agencies for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) harboring the 17p deletion.
Read More
Idelalisib/Ofatumumab Combo Effective in Phase III CLL Trial
June 24th 2015Treatment with the combination of idelalisib and ofatumumab demonstrated an improvement in objective response rates, progression-free survival, and lymph node response compared with ofatumumab alone in patients with previously treated chronic lymphocytic leukemia.
Read More